CONCORD, Calif. — Cerus Corp. has signed a new four-year agreement with France’s national blood service to supply its INTERCEPT Blood System, extending a long-standing partnership focused on improving transfusion safety.
The agreement with Établissement Français du Sang covers Cerus’ pathogen inactivation system for platelets and plasma, along with its next-generation LED-based INT200 illumination device.
“We are proud to announce a new four-year supply agreement with the French Blood Establishment,” said Christian Boutemy, vice president of international commercial operations at Cerus. “EFS has been a global leader in the adoption of pathogen inactivation technologies to help safeguard the blood supply and enhance patient safety. This agreement further underscores our shared, enduring commitment to ensuring safe transfusions for patients.”
The French Blood Establishment distributes roughly 330,000 units of platelets each year through 13 regional centers across mainland France and its overseas territories.
Cerus’ INTERCEPT system has been used in France since 2006, with nationwide adoption expanding in 2017. The technology is also deployed in overseas regions including La Réunion, Guadeloupe, and Martinique, where it has been used to help maintain safe blood supplies during outbreaks of mosquito-borne diseases such as chikungunya, dengue, and Zika.
The renewed agreement highlights continued demand for pathogen reduction technologies aimed at minimizing the risk of transfusion-transmitted infections.
